On October 30, 2019 GSK reported sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*) (Press release, GlaxoSmithKline, OCT 30, 2019, View Source [SID1234550037]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial highlights
Reported Group sales £9.4 billion +16% AER, +11% CER (Pro-forma growth +6% CER*); Pharmaceuticals £4.5 billion +7% AER, +3% CER; Vaccines £2.3 billion +20% AER, +15% CER; Consumer Healthcare
£2.5 billion +30% AER, +25% CER (Pro-forma growth +3% CER*)
Total Group operating margin 22.9%; Adjusted Group operating margin 29.7% reflecting increased spending on R&D and priority assets, and the impact of generic Advair in the US, partly offset by Vaccines performance (Pharmaceuticals 24.1%; Vaccines 50.3%; Consumer Healthcare 24.3%)
Total EPS 31.4p +9% AER, -1% CER, Adjusted EPS 38.6p +9% AER, +1% CER reflecting operating performance and lower effective tax rate offset by increased profit allocation to non-controlling interests
9 months net cash flow from operations £4.6 billion. Free cash flow £2.5 billion
19p dividend declared for the quarter, continue to expect 80p for FY19
Consumer Healthcare JV with Pfizer completed 31 July creating new world leader in Consumer Healthcare
2019 Adjusted EPS guidance improved to expectation of around flat at CER from a decline of -3% to -5%
Product and pipeline highlights
Shingrix sales £535 million +87% AER, +76% CER driven by continuing strong execution in the US
Total Respiratory sales £806 million +25% AER, +19% CER. Nucala £203 million +40% AER, +33% CER
Trelegy £139 million +>100% AER, +>100% CER
Total HIV sales £1.3 billion, +5% AER, flat at CER. Two-drug regimen sales £119 million
Continued progress to strengthen and advance R&D pipeline including:
Oncology:

Positive data presented at ESMO (Free ESMO Whitepaper) from PRIMA trial of Zejula monotherapy showing significant improvement in PFS in women with ovarian cancer regardless of biomarker status. On track to file by end 2019
Positive headline data from pivotal DREAMM-2 study of belantamab mafodotin (GSK2857916) for multiple myeloma. On track to file by end 2019
Positive data from GARNET study of dostarlimab for advanced or recurrent endometrial cancer. On track to file by end 2019
Positive data presented at ESMO (Free ESMO Whitepaper) on GSK3359609 (ICOS receptor agonist) plus pembrolizumab in head and neck squamous cell carcinoma. Phase II/III registrational trial announced
Respiratory:

Nucala approved in EU for self-administration by patients with severe eosinophilic asthma
Trelegy Ellipta submitted to the FDA for use in patients with asthma
HIV:

Long-acting injectable cabotegravir + rilpivirine submitted to EMA as the first monthly treatment for HIV
Positive phase III results from ATLAS-2M study of cabotegravir + rilpivirine administered every 8 weeks
Other:

Phase III start for first-in-class antibiotic, gepotidacin, in uncomplicated urinary tract infection and urogenital gonorrhoea
Daprodustat filed in Japan for patients with renal anaemia due to chronic kidney disease

Emma Walmsley, Chief Executive Officer, GSK said:
"GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance. This quarter we have continued to strengthen our pipeline and have advanced assets in Respiratory, HIV and, notably, Oncology, where we are on track to file three innovative medicines by year end, following positive pivotal trial data. We also achieved a significant milestone with the completion of our new Consumer Healthcare Joint Venture with Pfizer, to create a new world leading consumer healthcare business."